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ABSTRACT 
Objective 
To investigate factors affecting dose and plasma levels in patients taking lamotrigine 
discharged from a mental health Trust.  
Method 
All patients discharged on lamotrigine between October 2007 and September 2012 were 
identified using the pharmacy dispensing database. We recorded demographic details, 
lamotrigine dose and plasma levels and co-prescribed medication. 
Results 
During the designated period, 187 patients were discharged on lamotrigine of whom 117 
had their plasma levels recorded. The mean lamotrigine daily dose was 226.1mg (range, 
12.5 – 800.0mg) and the mean plasma level 5.9mg/L (range, 0.8 – 18.1mg/L). Gender, 
ethnicity, diagnosis and smoking status had no significant effect on dose or plasma levels. 
Patients taking an enzyme inducing drug (n = 6) had significantly lower plasma levels 
[mean(SD) 3.40mg/L(1.54)] than those not taking enzyme inducers [(n = 111), 
6.03mg/L(3.13), p = 0.043]. Patients taking an enzyme inhibiting drug (n=23) had 
significantly higher levels [7.47mg/L (3.99)] than those not taking an inhibitor [(n = 94), 
5.52mg/L (2.75), p=0.035]. A weak association was found between lamotrigine dose and 
lamotrigine plasma level (r = 0.318, p = 0.001). An ANOVA analysis revealed that the 
indication for prescribing lamotrigine had a significant effect on the mean lamotrigine dose 
(p = 0.026). Clozapine augmentation was associated with the highest mean dose of 
lamotrigine (280.0mg/day vs 231.9mg/day for bipolar affective disorders and 200.1mg/day 
for ‘other’ indications). 
Conclusion 
Monitoring plasma levels of lamotrigine helps to assess compliance but may also assist in 
dosing, especially in patients taking enzyme inducing or inhibiting co-administered drugs.  
Keywords:  Lamotrigine, lamotrigine dose-response relationship, therapeutic drug 
monitoring, drug interactions 
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Introduction 
Lamotrigine is an anticonvulsant which entered the market in 1994 as an add on treatment 
for seizure disorders. Currently it is licensed for the adjunctive or monotherapy treatment of 
various seizure disorders in both adults and children. In adults it is indicated for the 
prevention of depressive episodes in bipolar I disorder [GlaxoSmithKline UK, 2015]. Also not 
uncommonly in mental health, lamotrigine is used off-licence to augment clozapine in 
patients who have refractory schizophrenia and have shown an inadequate response to 
clozapine monotherapy [Tiihonen J et al., 2003]. It is also employed to act as prophylaxis 
against seizures in susceptible patients when clozapine plasma levels are above 500-600 
micrograms per litre [Varma S et al., 2011].  
Lamotrigine’s mechanism of action is largely unknown. However, it is believed to block 
voltage-gated sodium channels and calcium channels leading to the stabilisation of 
presynaptic neuronal membranes and inhibiting the release of the excitory 
neurotransmitter, glutamate [Braga MF et al., 2002; Stefani A et al., 1996]. 
Lamotrigine is metabolised in the liver primarily by conjugating with glucuronic acid to form 
the inactive metabolite 2-N-glucuronide [Rambeck B et al., 1993]. Uridine 5'-diphospho-
glucuronosyltransferase 1A4 (UGT1A4) and UGT 2B7 are the enzymes involved in this 
reaction [Magdalou J et al., 1992; Rowland A et al., 2006]. Other drugs and their metabolites 
that involve this metabolic route may show altered metabolism or affect the metabolism of 
lamotrigine due to competition for this pathway. As the metabolism of lamotrigine does not 
depend upon any cytochrome P450 enzymes, the possibility for drug interactions are 
generally limited [Rambeck B et al., 1993]. However, lamotrigine does have some clinically 
relevant interactions. 
Upon starting lamotrigine for any indication, the dose needs to be titrated slowly to a 
maintenance dose to reduce the risk of developing a serious rash. The maintenance 
monotherapy dosage of lamotrigine in epilepsy ranges typically between 100 – 200mg daily. 
However, when used with an adjunctive drug that inhibits lamotrigine glucuronidation (such 
as valproate) the titration of lamotrigine needs to be slower and lower maintenance doses 
of lamotrigine may be required. Conversely, when lamotrigine is administered with a drug 
Dose and plasma level of lamotrigine 
 
4 
 
that can induce its glucuronidation (such as carbamazepine) the initial starting dose of 
lamotrigine is higher and the final maintenance dose of lamotrigine may also be higher.  
For maintenance treatment of bipolar I disorder 200mg is the recommended target dose for 
lamotrigine[GlaxoSmithKline UK, 2015]. Although licensed only for the prophylaxis of bipolar 
I depression it is also used off-label for the acute treatment of this disorder. The advantage 
over antidepressants is that lamotrigine does not induce switching or rapid cycling [Taylor D 
et al., 2015]. In practice, it is also used as an adjunct to other mood stabilisers. For clozapine 
augmentation doses of lamotrigine 25-300mg have been recommended [Taylor D et al., 
2015]. 
A therapeutic plasma concentration target range is not established for lamotrigine. 
However, a therapeutic range of 2.5-15mg/L has been suggested in epilepsy [Cohen AF et 
al., 1987; Johannessen SI et al., 2003; Kilpatrick ES et al., 1996; Lardizabal DV et al., 2003]. It 
is believed that levels above 15mg/L maybe associated with toxicity [Morris RG et al., 1998]. 
The aim of this survey was to determine in a mental health setting doses of lamotrigine 
prescribed, the resulting plasma levels and the factors that may affect these parameters. 
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Method 
Patients discharged on lamotrigine between October 2007 and September 2012 were 
identified from the pharmacy electronic dispensing database system (JAC) of the South 
London and Maudsley NHS Foundation Trust (SLaM). SLaM is an inner city Trust serving a 
diverse population of 1.2 million people with areas of high unemployment and immigration. 
The dose of lamotrigine and any co-administered medication were noted. Patient details 
such as age, diagnosis, smoking status and reasons for taking lamotrigine were obtained 
from the patient electronic clinical notes (electronic patient journey system – ePJs). 
Lamotrigine plasma level and the levels of any other available co-administered medication 
were obtained from the patient plasma level record system (PROL). 
Statistical analysis 
All statistical analyses were performed using Statistical Package for the Social Sciences 
(SPSS) version 22.  Normal Q – Q plot was used to assess normality of the outcome 
variables. For descriptive statistics, categorical variables were presented as number of cases 
(n) and percentage (%), continuous variables as mean and standard variation. T-test 
(independent samples) was employed for the comparison of two groups. The analysis of 
variance (ANOVA) was used for the comparison of three groups or more for the continuous 
variables. The Pearson correlation test was employed to ascertain the association between 
the continuous variables. Significant results were shown by a p value less than 0.05. 
The Drugs and Therapeutics Committee confirmed this as a service evaluation so ethics 
approval was not required. All data were anonymised before analysis. 
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Results 
The characteristics of study subjects are shown in Table 1. There were 189 patients 
discharged from SLaM on lamotrigine in the five-year period from October 2007 and 
September 2012. Two patients were not included in the study because it was unclear 
whether lamotrigine was ever actually prescribed. Table 2 lists the ‘other’ diagnoses that 
were recorded. 
The mean lamotrigine daily dose was 226.1mg (range, 12.5 – 800.0mg). Clozapine 
augmentation was associated with the largest mean dose of lamotrigine as charted in figure 
1. Overall, 117 patients had their plasma levels recorded and the mean plasma level was 
5.9mg/L (range, 0.8 – 18.1mg/L). Table 3 records the mean lamotrigine daily dose and mean 
plasma levels for the different patient characteristics.  
No association was found between patient’s age and dose of lamotrigine (Pearson 
correlation r = -0.063 (p = 0.395), N = 187).  Similarly, no association was discovered 
between age and plasma level of lamotrigine r = - 0.087 (p = 0.350), N = 117. A weak 
association was determined between lamotrigine dose and lamotrigine plasma level r = 
0.318 (p = 0.001), N = 117, see figure 2. 
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Table 1. Characteristics of study sample 
Demographics 
 
N = 187 
 
Characteristics N (%) 
Gender 
Male 122 (65.2) 
Female 65(34.8) 
Ethnicity 
Asian 8(4.3) 
Black  23(12.3) 
White 156(83.4) 
Age (Years) 
Mean  46.6 
Range 13 - 90 
Standard deviation 17.4 
Smoking status 
Smoker 99(52.9) 
Non-smoker 49(26.2) 
Don’t know 39(20.9) 
Reason for lamotrigine 
Antiepileptic (Clozapine level >0.5mg/L) 11(5.9) 
Bipolar affective disorder/TRD 52(27.8) 
Clozapine augmentation 29(15.5) 
Other 87(46.5) 
TRS AP augmentation 8(4.3) 
Diagnosis 
Bipolar affective disorder 46(24.6) 
Schizoaffective disorder 15(8.0) 
Schizophrenia/TRS 31(16.6) 
Other  95(50.8) 
Taking an enzyme inducer 
Yes 10(5.3) 
No 177(94.7) 
Taking an enzyme inhibitor  
Yes 27(14.4) 
No 160(85.6) 
TRD: treatment resistant depression, TRS AP: treatment resistant schizophrenia treated with 
an antipsychotic other than clozapine, TRS: treatment resistant schizophrenia 
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Table 2. List of ‘other’ diagnoses patients had who were discharged on lamotrigine 
Other diagnoses N = 95 
Anorexia nervosa 
Asperger’s syndrome 
Cyclothymia 
Dementia in Alzheimer’s disease with late onset 
Emotionally unstable personality disorder 
Generalised anxiety disorder, agoraphobia, obsessive compulsive disorder 
Mental retardation, pervasive development disorder 
Mixed obsessional thoughts and acts 
Mental and behavioural disorders due to use of cannabinoids/opioids/alcohol  
Organic personality behavioural disorder 
Post-traumatic stress disorder 
Persistent delusional disorder 
Recurrent depressive disorder with or without psychotic symptoms 
Somatisation disorder 
 
Table 3. Mean daily dose and mean plasma level of lamotrigine for different patient 
characteristics 
Characteristic Lamotrigine dose (mg) Lamotrigine concentration (mg/l) 
Mean(SD) T-test (df) P value Mean(SD) T-test (df) P value 
Gender       
Female 225.39(156.47) -0.078(185) 0.938 5.93(3.34) 0.151(115) 0.093 
Male 227.31(164.69)   5.84(2.62)   
Ethnicity 
Black & Asian 
White 
 
210.49(167.43) 
229.15(157.58) 
 
-0.596(185) 
 
 
0.552 
 
6.83(2.64) 
5.76(3.17) 
 
1.28(185) 
 
0.552 
Enzyme inducer       
Yes 270.00(249.39) 0.583(9.386)* 0.574 3.40(1.54) -2.047(115) 0.043 
No 223.57(152.97)   6.03(3.13)   
Enzyme inhibitor 
Yes 
No 
 
200.93(138.59)  
230.30(162.13) 
 
-0.888(185) 
 
0.376 
 
7.47(3.99) 
5.52 (2.75) 
 
2.218(27.337)* 
 
0.035 
Smoking status 
Yes 
No 
 
240.51(170.58) 
192.86(140.22) 
 
1.692(146) 
 
0.093 
 
 
5.88(2.91) 
5.70(3.01) 
 
0.282(89) 
 
0.779 
Diagnosis 
Scz/SA 
BAD 
Other 
 
250.27(172.41) 
212.72(145.95) 
226.06(158.60) 
 
0.746(2,184)# 
 
0.476 
 
5.95(2.59) 
6.86(3.97) 
5.27(2.71) 
 
2.641(2,114)# 
 
0.076 
Reasons for lamotrigine       
BAD/TRD 231.92(160.18) 3.708(2,184)# 0.026 6.57(3.78) 1.381(2,114) 0.256 
Clozapine augmentation 280.00(182.68)   5.75(2.46)   
Other 200.13(142.41)   5.47(2.87)   
Significant results are in bold (p <0.05); * Welch’s T-test; # ANOVA F test; Scz is schizophrenia, SA is schizoaffective disorder; BAD is bipolar 
affective disorder; TRD treatment resistant depression 
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Figure 1. Mean daily dose of lamotrigine for the reasons for taking lamotrigine 
 
 
Figure 2. Scatterplot for lamotrigine dose and plasma concentration r = 0.318 (p = 0.001) 
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Discussion  
Main findings 
The mean daily dose of lamotrigine was found to be 226.1mg (range, 12.5 – 800.0mg) and 
the mean daily plasma level 5.9mg/L (range, 0.8 – 18.1mg/L). A weak association was shown 
between lamotrigine daily dose and lamotrigine plasma levels. Our main finding was that 
patients taking an enzyme-inducing drug with lamotrigine had significantly lower 
lamotrigine plasma levels than those not taking one, despite receiving higher doses. 
Conversely patients taking an enzyme inhibiting drug had significantly higher levels than 
those not taking such drugs despite lower doses. The reasons for being prescribed 
lamotrigine was significantly associated with the mean lamotrigine dose, with clozapine 
augmentation being associated with the highest mean dose. Gender, ethnicity and smoking 
status were found to have no significant effect on lamotrigine’s dose or plasma levels. This 
study also highlighted the range of use of lamotrigine in several psychiatric illnesses. In fact, 
its use in the large majority of cases was off-label; bipolar affective disorder accounted for 
24.6%, schizoaffective disorder 8.0%, schizophrenia 16.6% and others 50.8%. 
Lamotrigine’s plasma concentrations 
The Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP) 
guidelines [Hiemke C et al., 2011] acknowledges that there are no established plasma level 
target range for lamotrigine’s mood stabilising effects.  They do however recommend 
therapeutic drug monitoring and suggest a range of 3 – 14 mg/ml, the same as what is 
suggested for monitoring lamotrigine’s anticonvulsant effects. For the bulk of our patients 
who had had their lamotrigine levels measured, their levels fell within this suggested range. 
However, 17 patients had lamotrigine plasma levels below the suggested therapeutic 
threshold of 3mg/L. The implications for having plasma levels this low is unknown.   
Our study suggested a weak association between lamotrigine dose and lamotrigine plasma 
level but clearly the impact of enzyme inducers and inhibitors is important here. 
Lamotrigine’s relevant clinical interactions potentially requiring dose adjustments 
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The interaction between lamotrigine and valproate is widely known. The dosing regimen for 
lamotrigine is changed substantially when these two drugs are prescribed together. Both 
drugs share glucuronidation via UGT as a major metabolite pathway and the interaction is 
thought to result from competitive inhibition of this enzyme group. The magnitude of the 
interaction was first quantified in a cross over study of 18 volunteer subjects who received 
valproate (as divalproex) and three doses of lamotrigine 50mg, 100mg, and 150mg/day 
[Anderson GD et al., 1996]. It was shown that when compared to previous studies where 
subjects received only lamotrigine, the co-administration of valproate increased 
lamotrigine’s half-life from 26.4 hours to 69.6 hours and the clearance values were 
decreased from 0.48 to 0.20 ml/min/kg respectively. The addition of lamotrigine to 
valproate however, also resulted in the increased clearance of valproate with a 25% 
decrease in its plasma concentration. The nature of this bi-directional interaction cannot be 
explained by competitive inhibition alone. It was later studies by Rowland and co-workers 
that showed that glucuronidation of lamotrigine was metabolised by both UGT1A4 and 
UGT2B7 [Rowland A et al., 2006]. Valproate is a known substrate of UGT2B7 but was shown 
not to affect the function of UGT1A4. The authors concluded that valproate decreased 
lamotrigine’s clearance via inhibition of UGT2B7 and lamotrigine increased valproate’s 
clearance possibly by induction of UGT1A4.  
In practice, the co-prescribing of valproate should provoke a halving of the lamotrigine dose. 
Our study found that there was no significant difference between the doses of lamotrigine 
in patients taking an enzyme inhibitor and those not taking one. The enzyme-inhibiting 
group’s mean lamotrigine dose was 200.93mg daily which indicates that many patients were 
taking a higher dose than 200mg daily. The SPC for lamotrigine recommends a maximum 
dose of 200mg daily of lamotrigine when taken with valproate [GlaxoSmithKline UK, 2015]. 
Valproate was the main inhibitor taken by patients in our study. (Two patients were taking 
an enzyme-inhibiting drug other than valproate.) Our findings indicate that current guideline 
recommendations are not being followed. In one case a patient given valproate was also 
prescribed 400mg daily of lamotrigine; this patient’s lamotrigine level was 15mg/L. 
When a known inducer of lamotrigine metabolism, such as carbamazepine, phenytoin or 
hormonal contraceptives is taken with lamotrigine the lamotrigine dose should be doubled 
[GlaxoSmithKline UK, 2015]. In our survey no significant difference was found between the 
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doses of lamotrigine in patients taking an enzyme inducing drug and those not taking any. 
The doses were numerically higher in the enzyme-inducing group but only for one patient 
was the dose doubled. Not doubling the dose of lamotrigine in these circumstances can be 
predicted to afford subtherapeutic plasma levels. 
We found significantly lower lamotrigine plasma levels in patients taking an enzyme-
inducing drug than those not taking an enzyme inducer. Conversely, in patients taking an 
enzyme-inhibiting drug with lamotrigine we found significantly higher plasma levels of 
lamotrigine than those not taking an enzyme inhibitor. These findings indicate that 
therapeutic drug monitoring of lamotrigine would be helpful before and after an enzyme- 
inducing or an enzyme-inhibiting drug is added to an established dose of lamotrigine. The 
dose of lamotrigine could then be adjusted accordingly after the enzyme modifying drug is 
established.  
Clozapine augmentation 
Various pharmacological augmentation therapies have been suggested for patients with 
treatment-resistant schizophrenia showing inadequate response to clozapine [Taylor D et 
al., 2015]. Lamotrigine is one such augmentation therapy. Generally, the evidence bases for 
these therapies are poor. A part of lamotrigine’s mechanism of action involves inhibiting the 
release of the excitory neurotransmitter glutamate. Evidence points to dysfunctional 
glutamatergic neurotransmission in the pathophysiology of schizophrenia [Goff DC et al., 
2001; Goff DC et al., 2007]. Thus the interest in lamotrigine for the treatment of 
schizophrenia. Clinical studies have reported either the absence or a small effect of 
lamotrigine augmentation of clozapine [Goff DC et al., 2007; Heck AH et al., 2005; Zoccali R 
et al., 2007]. A meta-analysis by Tilhonen et al 2009 suggests a moderate effect size 
[Tiihonen J et al., 2009]. However another meta-analysis by Sommer et al 2012 [Sommer IE 
et al., 2011] found that the beneficial effect of lamotrigine disappeared after outlier 
removal. 
In our study clozapine, augmentation was associated with the largest mean dose of 
lamotrigine. This was unexpected as guidelines recommend lower doses (50 – 200mg) of 
lamotrigine for clozapine augmentation [Taylor D et al., 2015]. Lamotrigine has been shown 
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not to affect the plasma levels of clozapine significantly [Spina E et al., 2006] and vice versa 
[Reimers A et al., 2005].  
Effect of age, ethnicity, sex and smoking status 
Age, gender, ethnicity and smoking status were found not to have any significant effect on 
lamotrigine dose or plasma levels in our study.  
Reimer et al 2005 [Reimers A et al., 2005] found male gender and being 70 or over to be 
associated with greater lamotrigine plasma concentrations. They state that this significant 
effect of age was not found in previous studies as low numbers of elderly subjects were 
included. In our study we had 17 patients aged 70 or over. In Reimer’s and co. study they 
had 70 subjects aged 70 or over. With regards to gender even though a statistically 
significant effect was found the numerical value was low at 7%. The researchers postulate 
that this finding maybe coincidental or due to males tending to have a larger weight than 
females however acknowledging that evidence of weight effects and lamotrigine is lacking. 
They also suggest hormonal factors may explain this difference and call for more research 
on the effect of gender and body weight. 
Reinsberger et al 2008 [Reinsberger C et al., 2008] found smoking to have a significant effect 
on lamotrigine’s plasma levels and propose induction of UGT2B7 by tobacco as a possible 
mechanism. Smokers had lower levels than non-smokers. The clinical relevance of this 
interaction was not elucidated. 
Limitations 
This study had a number of limitations. No data were collected about clinical efficacy and 
adverse effects. Smoking status was underreported and not all patients had lamotrigine 
plasma levels done. The extent to which patients were adherent to all their prescribed 
medication was unknown. The duration of lamotrigine treatment was not determined; it is 
known that low lamotrigine levels could be observed in the first few weeks of taking due to 
lamotrigine auto-induction. This could be confounded with the small doses needed at the 
start of treatment or co-administration with an enzyme-inducing drug.  
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Conclusion 
Current dosing recommendations indicate that lamotrigine doses should be halved in 
individuals taking enzyme inhibitors and doubled in those on enzyme inducers. In our survey 
these recommendations were not always followed with the consequence that patients 
receive too high or too low a dose of lamotrigine respectively. Therapeutic drug monitoring 
of lamotrigine’s plasma concentrations is recommended to assist in dosing of lamotrigine 
particularly in patients taking co-administered enzyme inducing or enzyme inhibiting drugs. 
Prescribers used different doses of lamotrigine for different indications and lamotrigine was 
used almost entirely for off-label indications.  
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